Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering engineered cell and gene therapies, particularly for solid tumors. The company leverages its proprietary cytoDRiVE® platform, which utilizes drug-responsive domains (DRDs) to precisely control protein activity in cells using FDA-approved small-molecule drugs. This technology aims to enhance the efficacy and safety of treatments by enabling tunable protein expression. Obsidian Therapeutics is developing tumor-infiltrating lymphocyte (TIL) cell therapies, with its lead candidate, OBX-115, currently in clinical trials for advanced melanoma and non-small cell lung cancer (NSCLC). The company announced a definitive merger agreement with Galera Therapeutics in April 2026, becoming a publicly traded company on Nasdaq under the ticker 'OBX'. This merger was supported by a $350 million private placement to fund clinical operations through 2028. Obsidian Therapeutics has offices in Cambridge and Bedford, Massachusetts, USA. Sources: [1] https://intuitionlabs.ai/companies/biotech/obsidian-therapeutics [2] https://www.foresitecapital.com/portfolio/obsidian-therapeutics-inc/ [3] https://obsidiantx.com/ [4] https://www.businesswire.com/news/home/20260803549139/en/Obsidian-Therapeutics-Completes-Closing-of-Transaction-with-Galera-Therapeutics-and-Previously-Announced-Private-Placement-of-%24350-Million [5] https://startupintros.com/orgs/obsidian-therapeutics [6] https://tracxn.com/d/companies/obsidiantherapeutics/__gv0si6OxT5M8G_ipEBLhju3knJSGytY5xGdJY4cdLKA